Market Closed -
Oslo Bors
10:45:00 2024-04-26 am EDT
|
5-day change
|
1st Jan Change
|
23.9
NOK
|
+1.70%
|
|
0.00%
|
+2.58%
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Capitalization
1 |
220
|
330.8
|
461.2
|
773.8
|
859.4
|
700.6
|
Enterprise Value (EV)
1 |
134.7
|
10.08
|
142.7
|
698.7
|
825
|
748.4
|
P/E ratio
|
3.13
x
|
-3.57
x
|
6.97
x
|
-7.97
x
|
34.6
x
|
-144
x
|
Yield
|
-
|
-
|
9.62%
|
2.87%
|
3.87%
|
4.75%
|
Capitalization / Revenue
|
1.24
x
|
1.65
x
|
2.02
x
|
3.05
x
|
3.08
x
|
2.3
x
|
EV / Revenue
|
0.76
x
|
0.05
x
|
0.63
x
|
2.75
x
|
2.96
x
|
2.45
x
|
EV / EBITDA
|
17
x
|
13.6
x
|
5.91
x
|
13
x
|
19.3
x
|
140
x
|
EV / FCF
|
2.78
x
|
1.76
x
|
-2.06
x
|
-15.3
x
|
-27.1
x
|
-9.19
x
|
FCF Yield
|
35.9%
|
56.7%
|
-48.6%
|
-6.54%
|
-3.69%
|
-10.9%
|
Price to Book
|
1.83
x
|
0.95
x
|
1.12
x
|
2.84
x
|
3.12
x
|
2.56
x
|
Nbr of stocks (in thousands)
|
17,055
|
44,345
|
44,345
|
44,345
|
44,345
|
44,345
|
Reference price
2 |
12.90
|
7.460
|
10.40
|
17.45
|
19.38
|
15.80
|
Announcement Date
|
4/16/18
|
4/26/19
|
4/23/20
|
4/23/21
|
4/27/22
|
4/27/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net sales
1 |
177.1
|
200.5
|
228.1
|
253.9
|
278.6
|
304.9
|
EBITDA
1 |
7.921
|
0.74
|
24.16
|
53.92
|
42.79
|
5.331
|
EBIT
1 |
5.219
|
-4.606
|
16.77
|
45.56
|
33.25
|
-6.096
|
Operating Margin
|
2.95%
|
-2.3%
|
7.35%
|
17.94%
|
11.93%
|
-2%
|
Earnings before Tax (EBT)
1 |
7.36
|
-85.3
|
84.04
|
-124.3
|
32
|
-6.009
|
Net income
1 |
70.4
|
-73.63
|
66.2
|
-96.96
|
24.87
|
-4.716
|
Net margin
|
39.76%
|
-36.72%
|
29.02%
|
-38.19%
|
8.92%
|
-1.55%
|
EPS
2 |
4.128
|
-2.089
|
1.493
|
-2.190
|
0.5600
|
-0.1100
|
Free Cash Flow
1 |
48.38
|
5.717
|
-69.32
|
-45.72
|
-30.41
|
-81.39
|
FCF margin
|
27.33%
|
2.85%
|
-30.39%
|
-18.01%
|
-10.92%
|
-26.7%
|
FCF Conversion (EBITDA)
|
610.81%
|
772.58%
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
68.73%
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
1.000
|
0.5000
|
0.7500
|
0.7500
|
Announcement Date
|
4/16/18
|
4/26/19
|
4/23/20
|
4/23/21
|
4/27/22
|
4/27/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
47.7
|
Net Cash position
1 |
85.3
|
321
|
318
|
75.2
|
34.4
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
8.954
x
|
Free Cash Flow
1 |
48.4
|
5.72
|
-69.3
|
-45.7
|
-30.4
|
-81.4
|
ROE (net income / shareholders' equity)
|
3.55%
|
-28.9%
|
17.3%
|
-28.3%
|
9.07%
|
-1.72%
|
ROA (Net income/ Total Assets)
|
1.28%
|
-0.79%
|
2.09%
|
6.89%
|
6.34%
|
-1.03%
|
Assets
1 |
5,518
|
9,359
|
3,171
|
-1,406
|
391.9
|
458.2
|
Book Value Per Share
2 |
7.050
|
7.870
|
9.320
|
6.140
|
6.220
|
6.160
|
Cash Flow per Share
2 |
5.000
|
7.230
|
7.210
|
1.740
|
0.8100
|
0.0300
|
Capex
1 |
35.6
|
18.1
|
18.4
|
53.1
|
31.9
|
64.3
|
Capex / Sales
|
20.08%
|
9.01%
|
8.05%
|
20.91%
|
11.46%
|
21.09%
|
Announcement Date
|
4/16/18
|
4/26/19
|
4/23/20
|
4/23/21
|
4/27/22
|
4/27/23
|
|
1st Jan change
|
Capi.
|
---|
| +2.58% | 95.97M | | +19.62% | 43.34B | | +20.44% | 21.96B | | +10.86% | 14.09B | | +13.07% | 13.64B | | +37.46% | 11.43B | | -8.59% | 6.86B | | -0.05% | 6.79B | | -8.87% | 5.73B | | +8.46% | 5.22B |
Generic Pharmaceuticals
|